Nature Open Library is a new and different Open Innovation program launched by Pierre Fabre late 2015 to share its private plants' collection numbering over 15,000 samples and its expertise of the phyto-industrial value chain
VibioSphen is a biotechnology company specializing in infectious diseases. It will first carry out a targeted screening of Pierre Fabre's plants' collection in its core therapeutic field
Through this partnership, which could be extended beyond this first screening phase, the two companies highlight the growing dynamism of the economic environment of the Toulouse region in life sciences
Labège (France), Castres (France), April 14th 2016 - Pierre Fabre laboratories and VibioSphen, a young biotechnology company from the Toulouse region specializing in infectious disease, announced today the signature of a new partnership agreement within the framework of "Nature Open Library", a new and different Open Innovation program launched last December by Pierre Fabre to share its private plants' collection and its expertise of the whole phyto-industrial value chain with innovating companies from all sectors. Following a first partnership signed in February 2016 with the British biotechnology company Plasticell, this new collaboration is the second one that falls within the framework of this initiative.
VibioSphen will first screen Pierre Fabre's plants' collection, one of the most important in the industry, numbering over 15.000 classified samples and phyto-chemical compounds. Via this targeted screening, VibioSphen will try to identify new natural molecules which could be tested afterwards on several models of infectious diseases. Under the terms of the agreement, if this screening phase is carried out successfully, Pierre Fabre Laboratories will then become VibioSphen's preferred partners for the further development of identified molecules.
"This second partnership confirms the interest rouse by our Nature Open Library initiative. We are especially glad to implement it with a biotech company from the Toulouse region which makes its dynamism available for the further development of therapies in the field of infectious diseases, a medical field with the utmost importance not included in our R&D program but which could benefit from the given opportunities via our plants' collection", stated Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director commenting this new agreement.
"This partnership is a real opportunity for us to develop our portfolio of molecules. Through this collaboration, VibioSphen will benefit from the expertise of a major group like Pierre Fabre. The access to these natural extracts and to pre-qualified molecules will help us identify more quickly drug candidates. New therapies can be discovered via natural molecules to fight against antibiotic resistant bacteria", commented Maxime Fontanié, VibioSphen's CEO.
About Nature Open Library
Nature Open Library is a new and different Open Innovation program launched by Pierre Fabre Laboratories allowing them to share their expertise with innovative project initiators, from research and development to industrialization of plant active principles. In this context, Pierre Fabre Laboratories provide access to their private plant collection, one of the most important in the industry, numbering over 15.000 classified samples. This collection has been developed in accordance with biodiversity access regulations (Rio Convention and Nagoya Protocol). Within the framework of Nature Open Library, Pierre Fabre Laboratories offer to help its future partners to boost their innovative process by opening access to their interdisciplinary teams mastering the entire phyto-industrial value chain. For more information, please visit: https://nature-open-library-pierre-fabre.force.com
A propos de VibioSphen
VibioSphen is a SME healthcare biotechnology in infectious diseases founded in 2014. It focuses its activities on the challenge of antibiotic resistance and nosocomial infections. To meet this goal VibioSphen proposes a dual business model with two complementary activities: service offer (CRO, Contract Research Organization), with a large panel of optimized preclinical infectious models (bacteria, fungi and virus) and Research & Innovation (R&I) to develop new immune modulator treatments complementary to antibiotics.
Vibiosphen combines expertise in microbiology, molecular biology and pharmacology (in vitro and in vivo) with experience in drug R&D in the field of infectious diseases, immunomodulation and host-pathogen interaction. As a biotechnology company, we conduct research into potential future therapies against multi-resistant bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella, Acinetobacter, Staphylococcus aureus.;.) with a portfolio of 4 promising immunomodulatory pre-candidates and provide services drawing on cutting-edge technology to create predictive and translational models (pneumonia, Urinary Tract Infection, septicemia...) for studying small molecules or biologics.
VibioSphen is currently completing his portfolio with natural products. These two activities complement and drive each other in terms of research and innovation.
Our team has extensive experience in the field of infectious diseases in the pharmaceutical industry. By pooling complementary skills, our team provides the highest level of technical expertise in producing predictive pharmacological models and anticipates the requirements for the development of a new molecule.
For more information about VibioSphen, please visit: http://vibiosphen.com/
About Pierre Fabre Laboratories
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Within the framework of their Open Innovation strategy, Pierre Fabre laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CNRS, Inserm, ...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay,...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho, ...) and biotech companies (Array, BioPharma, AbCheck, Cellectar, ...).
Through the Group's controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999, and around 8% by the company's employees and balance is held as treasury stock.
VibioSphen is a biotechnology company specializing in infectious diseases. It will first carry out a targeted screening of Pierre Fabre's plants' collection in its core therapeutic field
Through this partnership, which could be extended beyond this first screening phase, the two companies highlight the growing dynamism of the economic environment of the Toulouse region in life sciences
Labège (France), Castres (France), April 14th 2016 - Pierre Fabre laboratories and VibioSphen, a young biotechnology company from the Toulouse region specializing in infectious disease, announced today the signature of a new partnership agreement within the framework of "Nature Open Library", a new and different Open Innovation program launched last December by Pierre Fabre to share its private plants' collection and its expertise of the whole phyto-industrial value chain with innovating companies from all sectors. Following a first partnership signed in February 2016 with the British biotechnology company Plasticell, this new collaboration is the second one that falls within the framework of this initiative.
VibioSphen will first screen Pierre Fabre's plants' collection, one of the most important in the industry, numbering over 15.000 classified samples and phyto-chemical compounds. Via this targeted screening, VibioSphen will try to identify new natural molecules which could be tested afterwards on several models of infectious diseases. Under the terms of the agreement, if this screening phase is carried out successfully, Pierre Fabre Laboratories will then become VibioSphen's preferred partners for the further development of identified molecules.
"This second partnership confirms the interest rouse by our Nature Open Library initiative. We are especially glad to implement it with a biotech company from the Toulouse region which makes its dynamism available for the further development of therapies in the field of infectious diseases, a medical field with the utmost importance not included in our R&D program but which could benefit from the given opportunities via our plants' collection", stated Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director commenting this new agreement.
"This partnership is a real opportunity for us to develop our portfolio of molecules. Through this collaboration, VibioSphen will benefit from the expertise of a major group like Pierre Fabre. The access to these natural extracts and to pre-qualified molecules will help us identify more quickly drug candidates. New therapies can be discovered via natural molecules to fight against antibiotic resistant bacteria", commented Maxime Fontanié, VibioSphen's CEO.
About Nature Open Library
Nature Open Library is a new and different Open Innovation program launched by Pierre Fabre Laboratories allowing them to share their expertise with innovative project initiators, from research and development to industrialization of plant active principles. In this context, Pierre Fabre Laboratories provide access to their private plant collection, one of the most important in the industry, numbering over 15.000 classified samples. This collection has been developed in accordance with biodiversity access regulations (Rio Convention and Nagoya Protocol). Within the framework of Nature Open Library, Pierre Fabre Laboratories offer to help its future partners to boost their innovative process by opening access to their interdisciplinary teams mastering the entire phyto-industrial value chain. For more information, please visit: https://nature-open-library-pierre-fabre.force.com
A propos de VibioSphen
VibioSphen is a SME healthcare biotechnology in infectious diseases founded in 2014. It focuses its activities on the challenge of antibiotic resistance and nosocomial infections. To meet this goal VibioSphen proposes a dual business model with two complementary activities: service offer (CRO, Contract Research Organization), with a large panel of optimized preclinical infectious models (bacteria, fungi and virus) and Research & Innovation (R&I) to develop new immune modulator treatments complementary to antibiotics.
Vibiosphen combines expertise in microbiology, molecular biology and pharmacology (in vitro and in vivo) with experience in drug R&D in the field of infectious diseases, immunomodulation and host-pathogen interaction. As a biotechnology company, we conduct research into potential future therapies against multi-resistant bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella, Acinetobacter, Staphylococcus aureus.;.) with a portfolio of 4 promising immunomodulatory pre-candidates and provide services drawing on cutting-edge technology to create predictive and translational models (pneumonia, Urinary Tract Infection, septicemia...) for studying small molecules or biologics.
VibioSphen is currently completing his portfolio with natural products. These two activities complement and drive each other in terms of research and innovation.
Our team has extensive experience in the field of infectious diseases in the pharmaceutical industry. By pooling complementary skills, our team provides the highest level of technical expertise in producing predictive pharmacological models and anticipates the requirements for the development of a new molecule.
For more information about VibioSphen, please visit: http://vibiosphen.com/
About Pierre Fabre Laboratories
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion Euros* in 2015, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns subsidiaries in 43 countries. In 2015, the company allocated 16 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Within the framework of their Open Innovation strategy, Pierre Fabre laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CNRS, Inserm, ...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay,...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho, ...) and biotech companies (Array, BioPharma, AbCheck, Cellectar, ...).
Through the Group's controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999, and around 8% by the company's employees and balance is held as treasury stock.
